REGENERX BIOPHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0014 USD | -97.32% |
|
0.00% | +16.67% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 18.66 | 19.91 | 18.41 | 59.38 | 22.97 | 19.94 |
| Enterprise Value (EV) 1 | 19.12 | 19.72 | 18.51 | 59.98 | 22.9 | 21.09 |
| P/E ratio | 71.8 x | -7.75 x | -12.3 x | -39 x | -13.9 x | -11.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 329 x | 286 x | 240 x | 774 x | 299 x | 260 x |
| EV / Revenue | 337 x | 283 x | 241 x | 781 x | 298 x | 275 x |
| EV / EBITDA | -13.3 x | -14.9 x | -14.7 x | -46.4 x | - | - |
| EV / FCF | 37.4 x | -10.4 x | -27.9 x | -115 x | -43.3 x | -46.3 x |
| FCF Yield | 2.68% | -9.66% | -3.58% | -0.87% | -2.31% | -2.16% |
| Price to Book | -4.53 x | -9 x | -7.87 x | -21 x | -10.3 x | -5.79 x |
| Nbr of stocks (in thousands) | 1,098 | 1,284 | 1,315 | 1,334 | 1,435 | 1,435 |
| Reference price 2 | 17.00 | 15.50 | 14.00 | 44.50 | 16.00 | 13.89 |
| Announcement Date | 3/29/18 | 3/29/19 | 3/20/20 | 3/2/21 | 3/30/22 | 4/11/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.0567 | 0.0697 | 0.0768 | 0.0768 | 0.0768 | 0.0768 |
| EBITDA 1 | -1.442 | -1.321 | -1.26 | -1.293 | - | - |
| EBIT 1 | -1.445 | -1.323 | -1.262 | -1.295 | -1.329 | -1.402 |
| Operating Margin | -2,550.01% | -1,899.56% | -1,643.89% | -1,686.46% | -1,730.71% | -1,826.44% |
| Earnings before Tax (EBT) 1 | 0.3851 | -1.994 | -1.404 | -1.523 | -1.598 | -1.727 |
| Net income 1 | 0.2865 | -1.994 | -1.404 | -1.523 | -1.598 | -1.727 |
| Net margin | 505.7% | -2,861.55% | -1,829.35% | -1,984.56% | -2,081.47% | -2,250.43% |
| EPS 2 | 0.2369 | -2.000 | -1.135 | -1.142 | -1.153 | -1.203 |
| Free Cash Flow 1 | 0.5115 | -1.906 | -0.6632 | -0.5213 | -0.5284 | -0.4558 |
| FCF margin | 902.92% | -2,735.5% | -864% | -679.08% | -688.36% | -593.85% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | 178.55% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/29/18 | 3/29/19 | 3/20/20 | 3/2/21 | 3/30/22 | 4/11/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.45 | - | 0.1 | 0.6 | - | 1.16 |
| Net Cash position 1 | - | 0.18 | - | - | 0.07 | - |
| Leverage (Debt/EBITDA) | -0.3143 x | - | -0.0755 x | -0.4627 x | - | - |
| Free Cash Flow 1 | 0.51 | -1.91 | -0.66 | -0.52 | -0.53 | -0.46 |
| ROE (net income / shareholders' equity) | -5.63% | 63% | 61.7% | 59% | 63.2% | 60.9% |
| ROA (Net income/ Total Assets) | -166% | -326% | -159% | -128% | -90.4% | -105% |
| Assets 1 | -0.1728 | 0.6123 | 0.8838 | 1.19 | 1.767 | 1.643 |
| Book Value Per Share 2 | -3.750 | -1.720 | -1.780 | -2.120 | -1.550 | -2.400 |
| Cash Flow per Share 2 | 0.1700 | 0.1800 | 0.4900 | 0.3200 | 0.8600 | 0.2000 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/29/18 | 3/29/19 | 3/20/20 | 3/2/21 | 3/30/22 | 4/11/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +16.67% | 2.11K | |
| -4.06% | 86.13B | |
| +1.97% | 39.82B | |
| +56.59% | 25.23B | |
| -13.56% | 15.36B | |
| -8.82% | 11.95B | |
| -15.32% | 11.6B | |
| -41.58% | 11.51B | |
| +6.14% | 8.71B | |
| -7.02% | 8.12B |
- Stock Market
- Equities
- RGRX Stock
- Financials RegeneRx Biopharmaceuticals, Inc.
